All News

Mina M. Fam, MD, discusses the significance of the FDA's recent approval of tebipenem pivoxil for patients with complicated urinary tract infections.

Enzalutamide plus talazoparib showed promising clinical activity in high-volume mHSPC, although with a notable toxicity burden.

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Rachel Rubin, MD, for a conversation on advocacy, sexual medicine, and the evolving role of urologists in women’s health.

Rahul Winayak, MD, discusses the prognostic and predictive value of microbial dysbiosis in patients receiving CBM588 plus first-line immune checkpoint inhibitor-based regimens for metastatic renal cell carcinoma.

Eugene Pietzak, MD, highlights results from a phase 2 study of pembrolizumab plus BCG for patients with very high-risk, BCG-naive high-grade T1 NMIBC who declined upfront radical cystectomy.

Preston C. Sprenkle, MD, discusses the unmet needs, emerging solutions, and longer-term vision for MRI in prostate cancer care.

Unwanaobong Nseyo, MD, MHS, discusses a retrospective analysis comparing treatment continuation outcomes with minimally invasive therapies for idiopathic overactive bladder.

Sandip Prasad, MD, discusses 3-year data from the phase 3 ENVISION trial evaluating mitomycin for intravesical solution for recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

In this episode of The UroOnc Minute, Lourdes Guerrios-Rivera, MD, discusses strategies to improve patient engagement and adherence during active surveillance for prostate cancer, highlighting the critical roles of education, communication, and structured follow-up.

Data from the RAMPART trial showed that durvalumab monotherapy missed the DFS threshold in resected RCC, though the combination with tremelimumab showed significant benefit.

Andrew J. Armstrong, MD, MSc, discusses efficacy results from a phase 2 study evaluating a chemoimmunotherapy regimen for patients with neuroendocrine or aggressive-variant metastatic prostate cancer.

The prospective RELIEF study will evaluate the safety and preliminary efficacy of IRE delivered via the NanoKnife System for BPH-related symptoms.

In this episode of Pearls & Perspectives, Thomas F. Stringer, MD, FACS, discusses his journey from private practice to academic urology, his priorities as incoming AUA president, and opportunities to improve men's health engagement and education.

The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.

Daniel J. George, MD, discusses the clinical significance of the FDA approval of capivasertib, practical considerations for PTEN testing and toxicity management, and the broader implications of precision medicine for patients with advanced prostate cancer.

Jenny Guo, MD, discusses data suggesting that hemi-HoLEP may be a viable treatment option for patients with prior pelvic radiation.

Daniel Eun, MD, discusses the future of reconstructive urology, highlighting the promise of telesurgery and AI-driven surgical technologies while emphasizing the practical barriers that must be addressed for widespread adoption.

Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant belzutifan plus pembrolizumab for clear cell renal cell carcinoma, describing the regimen as a major advancement in kidney cancer treatment.

Patients who developed ototoxicity during cisplatin treatment experienced less worsening of pure-tone audiometry thresholds in ears treated with ACOU085 compared with placebo-treated ears.

Data from the BREEZE trial support the efficacy, safety, and tolerability of the Zenflow Prostatic Spring for BPH-related LUTS.

The approval is supported by data from the phase 3 CAPItello-281 trial.

The application is supported by data from the phase 3 LITESPARK-022 trial.

In this episode of The UroOnc Minute, Carissa Chu, MD, discusses the prevalence, biology, prognostic significance, and emerging molecular targets of variant histologies in bladder cancer.

In this video, Benjamin H. Lowentritt, MD, FACS, discusses findings from the real-world OPTYX study, assessing testosterone suppression and recovery among patients receiving relugolix for advanced prostate cancer.

Long-term data from the phase 2 TROG 15.03 FASTRACK II trial support the safety and efficacy of stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Jonathan D. Harper, MD, discusses findings from a secondary analysis of the PUSH trial showing that modest increases in urine volume and lower urine osmolality were associated with reduced kidney stone recurrence, even when patients did not reach the guideline-recommended urine output target.

The approval adds another commercially available source of the PSMA-targeted radiotracer.